A retrospective analysis of discontinuation rates and reasons for discontinuation in multiple sclerosis patients treated with delayed-release dimethyl fumarate (Biogen ONE Support Program)

被引：0
|
作者：
Vorobeychik, G. [1 ]
Potts, J. [2 ]
Smith, M. [3 ]
Vlaicu, M. [3 ]
机构：
[1] Fraser Hlth Multiple Sclerosis Clin, Burnaby, BC, Canada
[2] Biogen, Cambridge, MA USA
[3] Biogen, Mississauga, ON, Canada
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P638
引用
收藏
页码：301 / 302
页数：2
相关论文
共 50 条
  • [11] Safety and Efficacy of Delayed-release Dimethyl Fumarate in Multiple Sclerosis Patients Treated in Routine Medical Practice: Interim Analysis of ESTEEM
    Everage, Nicholas J.
    Prada, Claudia
    Liu, Shifang
    Balashov, Konstantin
    Macdonell, Richard
    Windsheimer, Jorg
    Giles, Kathryn
    NEUROLOGY, 2017, 88
  • [12] Safety and efficacy of delayed-release dimethyl fumarate in multiple sclerosis patients treated in routine medical practice: interim analysis of ESTEEM
    Everage, N. J.
    Jones, C. C.
    Das, R.
    Hanna, J.
    Liu, S.
    Balashov, K.
    Macdonell, R.
    Windsheimer, J.
    Giles, K.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 715 - 716
  • [13] Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients with Multiple Sclerosis: An Observational Retrospective Study
    Abolfazli, Roya
    Sahraian, Mohammad Ali
    Tayebi, Atefeh
    Kafi, Hamidreza
    Samadzadeh, Sara
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [14] Lymphopenia in Multiple Sclerosis Patients Treated with Delayed-Release Dimethyl Fumarate: Analysis of 2 Electronic Health Record Databases in the US
    Wenten, Made
    Everage, Nicholas
    Somani, Teesta
    Lally, Cathy
    Juneja, Maneesh
    Eaton, Susan
    Prada, Claudia
    Dilley, Anne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 449 - 450
  • [15] Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS)
    Alroughani, Raed
    Das, Rajiv
    Penner, Natasha
    Pultz, Joe
    Taylor, Catherine
    Eraly, Satish
    PEDIATRIC NEUROLOGY, 2018, 83 : 19 - 24
  • [16] The potential of individualized patient coaching to optimize treatment with delayed-release dimethyl fumarate: a retrospective analysis of patients with multiple sclerosis treated in a real-world setting
    Begus-Nahrmann, Y.
    Niemczyk, G.
    Schmid, B.
    Maeurer, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 636 - 637
  • [17] Safety and effectiveness of delayed-release dimethyl fumarate in multiple sclerosis patients treated in routine medical practice: the first interim analysis of ESTEEM
    Everage, N. J.
    Prada, C.
    Liu, S.
    Balashov, K.
    Macdonell, R.
    Windsheimer, J.
    Giles, K.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 775 - 776
  • [18] Lymphopenia in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate: Analysis of Two United States Electronic Health Record Databases
    Wenten, Made
    Soman, Teesta
    Lally, Cathy
    Juneja, Maneesh
    Eaton, Susan
    Prada, Claudia
    Dilley, Anne
    NEUROLOGY, 2016, 86
  • [19] Effect of delayed-release dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis: a retrospective, multicentre, observational study (REALIZE)
    Buckle, G.
    Bandari, D.
    Greenstein, J.
    Gudesblatt, M.
    Khatri, B.
    Kita, M.
    Repovic, P.
    Riser, E.
    Weinstock-Guttman, B.
    Potts, J.
    Everage, N.
    von Hehn, C.
    Mann, M.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 781 - 782
  • [20] Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
    Kappos, L.
    Giovannoni, G.
    Gold, R.
    Phillips, J. T.
    Arnold, D. L.
    Hotermans, C.
    Zhang, A.
    Viglietta, V.
    Fox, R. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (04) : 664 - 671
12345